NVZMY vs. GMAB

Last updated Apr 2, 2026

Compare and contrast key facts about Novozymes AS (NVZMY) and Genmab A/S (GMAB).

Performance

NVZMY vs. GMAB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novozymes AS (NVZMY) and Genmab A/S (GMAB). The values are adjusted to include any dividend payments, if applicable.

NVZMY vs. GMAB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NVZMY Novozymes AS	-4.43%	14.29%	3.97%	12.42%	-38.46%	46.93%	18.10%	10.28%	-20.91%	69.59%
GMAB Genmab A/S	-11.62%	47.58%	-34.45%	-24.87%	7.13%	-2.71%	82.09%	35.54%	-0.61%	-0.04%

Fundamentals

Market Cap NVZMY : $28.38B GMAB : $18.31B
EPS NVZMY : $3.13 GMAB : $4.58
PE Ratio NVZMY : 19.19 GMAB : 5.94
PEG Ratio NVZMY : 0.11 GMAB : 0.18
PS Ratio NVZMY : 6.79 GMAB : 1.21
PB Ratio NVZMY : 2.61 GMAB : 0.49
Total Revenue (TTM) NVZMY : $4.16B GMAB : $14.32B
Gross Profit (TTM) NVZMY : $2.24B GMAB : $13.35B
EBITDA (TTM) NVZMY : $4.99B GMAB : $5.15B

Returns By Period

In the year-to-date period, NVZMY achieves a -4.43% return, which is significantly higher than GMAB's -11.62% return. Over the past 10 years, NVZMY has underperformed GMAB with an annualized return of 4.60%, while GMAB has yielded a comparatively higher 6.83% annualized return.

NVZMY

• 1D: 0.53%
• 1M: 4.83%
• YTD: -4.43%
• 6M: -1.80%
• 1Y: 5.95%
• 3Y*: 7.39%
• 5Y*: 0.29%
• 10Y*: 4.60%

GMAB

• 1D: 1.45%
• 1M: -8.20%
• YTD: -11.62%
• 6M: -14.32%
• 1Y: 45.87%
• 3Y*: -10.34%
• 5Y*: -3.74%
• 10Y*: 6.83%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NVZMY vs. GMAB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVZMY

NVZMY Risk / Return Rank: 44
NVZMY Sharpe Ratio Rank: 48
NVZMY Sortino Ratio Rank: 41
NVZMY Omega Ratio Rank: 41
NVZMY Calmar Ratio Rank: 45
NVZMY Martin Ratio Rank: 45

GMAB

GMAB Risk / Return Rank: 73
GMAB Sharpe Ratio Rank: 81
GMAB Sortino Ratio Rank: 74
GMAB Omega Ratio Rank: 72
GMAB Calmar Ratio Rank: 68
GMAB Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVZMY vs. GMAB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novozymes AS (NVZMY) and Genmab A/S (GMAB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NVZMY	GMAB	Difference
Sharpe ratio Return per unit of total volatility	0.22	1.33	-1.11
Sortino ratio Return per unit of downside risk	0.51	1.83	-1.32
Omega ratio Gain probability vs. loss probability	1.06	1.23	-0.17
Calmar ratio Return relative to maximum drawdown	0.19	1.35	-1.15
Martin ratio Return relative to average drawdown	0.38	3.81	-3.43
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NVZMY vs. GMAB - Sharpe Ratio Comparison

The current NVZMY Sharpe Ratio is 0.22, which is lower than the GMAB Sharpe Ratio of 1.33. The chart below compares the historical Sharpe Ratios of NVZMY and GMAB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NVZMY	GMAB	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.22	1.33	-1.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.01	-0.11	+0.12
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.17	0.20	-0.03
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	0.28	-0.36

Correlation

The correlation between NVZMY and GMAB is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NVZMY vs. GMAB - Dividend Comparison

NVZMY's dividend yield for the trailing twelve months is around 2.71%, while GMAB has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NVZMY Novozymes AS	2.71%	1.51%	1.03%	2.68%	1.68%	0.69%	0.91%	1.03%	1.10%	1.64%	0.95%	0.60%
GMAB Genmab A/S	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

NVZMY vs. GMAB - Drawdown Comparison

The maximum NVZMY drawdown since its inception was -86.29%, roughly equal to the maximum GMAB drawdown of -84.20%. Use the drawdown chart below to compare losses from any high point for NVZMY and GMAB.

Drawdown Indicators

	NVZMY	GMAB	Difference
Max Drawdown Largest peak-to-trough decline	-86.29%	-84.20%	-2.09%
Max Drawdown (1Y) Largest decline over 1 year	-29.64%	-28.98%	-0.66%
Max Drawdown (5Y) Largest decline over 5 years	-51.86%	-63.10%	+11.24%
Max Drawdown (10Y) Largest decline over 10 years	-51.86%	-63.10%	+11.24%
Current Drawdown Current decline from peak	-58.86%	-44.13%	-14.73%
Average Drawdown Average peak-to-trough decline	-57.40%	-30.93%	-26.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.99%	10.25%	+4.74%

Volatility

NVZMY vs. GMAB - Volatility Comparison

The current volatility for Novozymes AS (NVZMY) is 8.01%, while Genmab A/S (GMAB) has a volatility of 8.74%. This indicates that NVZMY experiences smaller price fluctuations and is considered to be less risky than GMAB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NVZMY	GMAB	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.01%	8.74%	-0.73%
Volatility (6M) Calculated over the trailing 6-month period	18.93%	24.56%	-5.63%
Volatility (1Y) Calculated over the trailing 1-year period	27.15%	34.92%	-7.77%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	27.79%	33.01%	-5.22%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.20%	35.13%	-7.93%

Financials

NVZMY vs. GMAB - Profitability Comparison

The chart below illustrates the profitability comparison between Novozymes AS and Genmab A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NVZMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novozymes AS reported a gross profit of -2.94B and revenue of -5.86B. Therefore, the gross margin over that period was 50.2%.

GMAB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Genmab A/S reported a gross profit of 6.21B and revenue of 6.72B. Therefore, the gross margin over that period was 92.3%.

NVZMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novozymes AS reported an operating income of 187.90M and revenue of -5.86B, resulting in an operating margin of -3.2%.

GMAB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Genmab A/S reported an operating income of 1.54B and revenue of 6.72B, resulting in an operating margin of 23.0%.

NVZMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novozymes AS reported a net income of 122.80M and revenue of -5.86B, resulting in a net margin of -2.1%.

GMAB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Genmab A/S reported a net income of 196.98M and revenue of 6.72B, resulting in a net margin of 2.9%.